Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
F-star Therapeutics, Inc. (SBPH)
|
Add to portfolio |
|
|
|
| Price: |
$9.67
| | Metrics |
| OS: |
22.0
|
M
| |
-79
|
% ROE
|
| Market cap: |
$213
|
M
| |
-579
|
% ROIC
|
|
Net cash:
|
$25.7
|
M
| |
$1.17
|
per share
|
|
EV:
|
$187
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($36.2)
|
M
| |
|
|
|
EBIT
|
($36.8)
|
M
| |
|
|
| EPS |
($2.01)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 21.2 | 11.3 | 0.0 | 0.0 | 0.0 | 0.4 | 0.9 | 0.7 |
| Revenue growth | 88.1% | | | | -100.0% | -62.8% | 28.2% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 21.2 | 11.3 | 0.0 | 0.0 | 0.0 | 0.4 | 0.9 | 0.7 |
| Gross margin | 100.0% | 100.0% | | | | 100.0% | 100.0% | 100.0% |
| Research and development | 28.8 | 14.1 | 23.3 | 19.8 | 13.1 | 14.0 | 7.5 | 6.1 |
| General and administrative | 23.1 | 19.5 | 9.8 | 8.7 | 8.2 | 5.7 | 5.0 | 2.4 |
| EBITA | -30.6 | -22.4 | -33.0 | -28.5 | -21.3 | -19.4 | -11.6 | -7.8 |
| EBITA margin | -144.6% | -198.9% | | | | -5512.5% | -1225.8% | -1057.7% |
| Amortization of intangibles | 0.1 | | | | | | | |
| EBIT | -30.7 | -22.4 | -33.0 | -28.5 | -21.3 | -19.4 | -11.6 | -7.8 |
| EBIT margin | -145.1% | -198.9% | | | | -5512.5% | -1225.8% | -1057.7% |
| Pre-tax income | -31.7 | -25.6 | -24.1 | -22.9 | -27.7 | -17.4 | -11.6 | -9.7 |
| Income taxes | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 1.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -31.3 | -25.6 | -24.1 | -22.9 | -27.7 | -17.4 | -11.6 | -9.7 |
| Net margin | -147.8% | -227.6% | | | | -4933.5% | -1222.4% | -1316.0% |
| |
| Diluted EPS | ($1.88) | ($9.69) | ($1.46) | ($1.56) | ($2.48) | ($2.39) | ($2.03) | ($3.11) |
| Shares outstanding (diluted) | 16.6 | 2.6 | 16.5 | 14.6 | 11.2 | 7.3 | 5.7 | 3.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|